Four clinical states were included in the model: ‘Alive without progression’, ‘Local Recurrence’, ‘Metastasis’, and ‘Death’. Individual patients are simulated by repeatedly sampling a patient profile, consisting of patient and tumour characteristics. The model tracks clinical events over time and takes patient and tumour features into account. The transitioning of patients between the health states is governed by personalized time dependent hazard rates, which were obtained by multi-state statistical modelling. Model outcomes are life years, QALYs, and costs. The time horizon is life time. A hospital perspective was taken. Two types cost-effectiveness evaluations were carried out using the model.

Heading 2

Four clinical states were included in the model: ‘Alive without progression’, ‘Local Recurrence’, ‘Metastasis’, and ‘Death’. Individual patients are simulated by repeatedly sampling a patient profile, consisting of patient and tumour characteristics. The model tracks clinical events over time and takes patient and tumour features into account. The transitioning of patients between the health states is governed by personalized time dependent hazard rates, which were obtained by multi-state statistical modelling. Model outcomes are life years, QALYs, and costs. The time horizon is life time. A hospital perspective was taken. Two types cost-effectiveness evaluations were carried out using the model.

Heading 3

Four clinical states were included in the model: ‘Alive without progression’, ‘Local Recurrence’, ‘Metastasis’, and ‘Death’. Individual patients are simulated by repeatedly sampling a patient profile, consisting of patient and tumour characteristics. The model tracks clinical events over time and takes patient and tumour features into account. The transitioning of patients between the health states is governed by personalized time dependent hazard rates, which were obtained by multi-state statistical modelling. Model outcomes are life years, QALYs, and costs. The time horizon is life time. A hospital perspective was taken. Two types cost-effectiveness evaluations were carried out using the model.

Heading 4

Four clinical states were included in the model: ‘Alive without progression’, ‘Local Recurrence’, ‘Metastasis’, and ‘Death’. Individual patients are simulated by repeatedly sampling a patient profile, consisting of patient and tumour characteristics. The model tracks clinical events over time and takes patient and tumour features into account. The transitioning of patients between the health states is governed by personalized time dependent hazard rates, which were obtained by multi-state statistical modelling. Model outcomes are life years, QALYs, and costs. The time horizon is life time. A hospital perspective was taken. Two types cost-effectiveness evaluations were carried out using the model.